Share on LinkedInShare on LinkedIn

ARTICLE · 07 AUGUST 2024

CAT Dismisses CMA Decision Based On Material Errors In Its Assessment Of Evidence

Macfarlanes LLP
Macfarlanes LLP
Contributor
Macfarlanes LLP

Macfarlanes LLP

Macfarlanes is a distinctive London-based law firm with a unique combination of services built and...

View firm profile
Explore more from Macfarlanes LLP

The Competition Appeal Tribunal overturned the CMA's decision on prochlorperazine, finding material errors in evidence assessment. The Tribunal ruled no market exclusion agreement existed, invalidating the CMA's £35m fines and related director disqualifications.

United KingdomAntitrust/Competition Law

The Competition Appeal Tribunal (Tribunal) has upheld appeals against the Competition and Markets Authority (CMA) infringement decision relating to the anti-nausea medication prochlorperazine (the Decision).

The Decision, issued in 2022, found that four companies had participated in an unlawful "market exclusion agreement" (MEA) in breach of the Chapter I Prohibition of the Competition Act 1998. The Tribunal found that the CMA had made “material errors” in its assessment of the evidence and overturned the findings of an MEA1. 

The decision

The CMA found that, from 2013 to 2018, Alliance Pharmaceuticals, Lexon, Focus and Medreich had participated in certain supply arrangements that amounted to an MEA. 

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from